Last update 08 May 2025

Protemix Corp. Ltd.

Dissolved
| Private Company|1999|California, United States

Overview

Related

4
Drugs associated with Protemix Corp. Ltd.
EN-122004
Target-
Mechanism
Insulin sensitizers
Active Org.-
Originator Org.
Protemix Corp. Ltd.
Active Indication-
Inactive Indication
Diabetes Mellitus, Type 2
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
PX-811013
Target
TNF-α
Mechanism
TNF-α inhibitors [+1]
Active Org.-
Originator Org.
Protemix Corp. Ltd.
Active Indication-
Inactive Indication
Diabetes Mellitus, Type 2 [+3]
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
GC-811011
Target-
Mechanism-
Active Org.-
Originator Org.
Protemix Corp. Ltd.
Active Indication-
Inactive Indication
Diabetes Complications
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
6
Clinical Trials associated with Protemix Corp. Ltd.
ACTRN12612000738820
/ CompletedPhase 1
A Single Center, Randomized, Double-Blind, Single-Dose, 2-Way Crossover, Dose Escalation Study of the Pharmacokinetics and Pharmacodynamics of PX811019 Compared with triethylenetetramine dihydrochloride in Normal Healthy Volunteers to compare the pharmacokinetic (PK) profiles: to determine the dosing relationship of PX811019 relative to triethylenetetramine dihydrochloride and to characterize the pharmacodynamic profile of urinary copper excretion in response to the study drug.
ACTRN12612000739819
/ CompletedPhase 2
ADDUCE: A randomized, double-blind, placebo-controlled, dose-ranging pilot study of the efficacy and safety of GC811007 in subjects with type-2 diabetes mellitus and heart failure: To assess safety and to determine whether treatment with GC811007 (400 and 1200 mg/day) improves exercise tolerance and indexes of cardiac structure and function
ACTRN12612000261819
/ CompletedPhase 2
Pilot Study of the Effects of GC811007 Administration on Copper and Trace Metal Metabolism in Non-diabetic Subjects and Patients with Type 2 Diabetes Mellitus: A Dose-response Sub-study of TETA on urinary copper excretion
100 Clinical Results associated with Protemix Corp. Ltd.
Login to view more data
0 Patents (Medical) associated with Protemix Corp. Ltd.
Login to view more data
100 Deals associated with Protemix Corp. Ltd.
Login to view more data
100 Translational Medicine associated with Protemix Corp. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
4
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
EN-122004
Diabetes Mellitus, Type 2
More
Discontinued
GC-811011
Diabetes Complications
More
Pending
PX-811013
 ( TNF-α )		Inflammation
More
Pending
EN-122006
Diabetes Mellitus, Type 2
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free